var data={"title":"Pancrelipase: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pancrelipase: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6719?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pancrelipase-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pancrelipase: Patient drug information&quot;</a> and <a href=\"topic.htm?path=pancrelipase-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pancrelipase: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206069\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Creon;</li>\n      <li>Pancreaze;</li>\n      <li>Pancrelipase (Lip-Prot-Amyl);</li>\n      <li>Pertzye;</li>\n      <li>Ultresa;</li>\n      <li>Viokace;</li>\n      <li>Zenpep</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206070\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cotazym;</li>\n      <li>Creon;</li>\n      <li>Pancrease MT;</li>\n      <li>Ultrase;</li>\n      <li>Ultrase MT;</li>\n      <li>Viokase</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206097\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Enzyme</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206071\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing should not exceed recommended maximum dosage set forth by the Cystic Fibrosis Foundation Consensus Conferences Guidelines. Adjust dose based on body weight, clinical symptoms, stool fat content, and the fat content of the diet. Allow several days between dose adjustments. Total daily dose reflects ~3 meals per day and 2 to 3 snacks per day, with half the mealtime dose given with a snack. Doses of lipase &gt;2,500 units/kg/meal, lipase &gt;10,000 units/kg/<b>day</b>, or lipase &gt;4,000 units/g fat daily should be used with caution and only with documentation of effectiveness by 3-day fecal fat measures indicating a significantly improved coefficient of fat absorption. Doses of lipase &gt;6,000 units/kg/meal are associated with colonic stricture and should be decreased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Pancreatic insufficiency due to conditions such as cystic fibrosis: </b> Oral (Creon, Pancreaze, Pertzye, Ultresa, Zenpep): Initial: Lipase 500 units/kg/meal. Dosage range: Lipase 500 to 2,500 units/kg/meal. Maximum: Lipase &le;2,500 units/kg/<b>meal</b> <b>or</b> lipase &le;10,000 units/kg/<b>day</b> <b>or</b> lipase &lt;4,000 units/g of fat daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pancreatic insufficiency due to chronic pancreatitis or pancreatectomy:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Creon: Initial: Lipase 500 units/kg/meal with individualized dosage titrations. In one clinical trial, 72,000 units/meal while consuming &ge;100 g of fat daily was used. Usually, half the prescribed dose for an individualized full meal should be given with each snack. Maximum: Lipase &le;2,500 units/kg/<b>meal or</b> lipase &le;10,000 units/kg/<b>day or</b> lipase &lt;4,000 units/g of fat daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Viokace (administer in combination with a proton pump inhibitor): Initial: Lipase 500 units/kg/meal with individualized dosage titration. In one clinical trial, 125,280 units/meal while consuming &ge;100 g of fat daily was used. Usually, half the prescribed dose for an individualized full meal should be given with each snack. Maximum: Lipase &le;2,500 units/kg/<b>meal or</b> lipase &le;10,000 units/kg/<b>day or</b> lipase &lt;4,000 units/g of fat daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pancreatic insufficiency (exocrine) due to pancreatic cancer (off-label dosing):</b> Oral: Initial: 25,000 to 50,000 units (lipase) per meal <b>or</b> 1,000 units (lipase)/kg/day or 4,000 units/5 to 7 g fat at each meal; escalate dose based on relief of symptoms; maximum dose: 2,500 units (lipase)/kg/meal (Damerla 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206085\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=pancrelipase-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Pancrelipase: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing should not exceed recommended maximum dosage set forth by the Cystic Fibrosis Foundation Consensus Conferences Guidelines. Adjust dose based on body weight, clinical symptoms, stool fat content, and the fat content of the diet. Allow several days between dose adjustments. Total daily dose reflects ~3 meals per day and 2 to 3 snacks per day, with half the mealtime dose given with a snack. Doses of lipase &gt;2,500 units/kg/meal, lipase &gt;10,000 units/kg/<b>day</b>, or lipase &gt;4,000 units/g fat daily should be used with caution and only with documentation of effectiveness by 3-day fecal fat measures indicating a significantly improved coefficient of fat absorption. Doses of lipase &gt;6,000 units/kg/meal are associated with colonic stricture and should be decreased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Pancreatic insufficiency due to conditions such as cystic fibrosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &le;1 year (Creon, Pancreaze, Pancrelipase, Pertzye, Ultresa, Zenpep): Oral: Manufacturer's labeling: Lipase 2,000 to 4,000 units per 120 mL of formula or per breastfeeding based on available dosage form:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Creon: 3,000 units per 120 mL formula or per breastfeeding</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pancreaze: 2,600 units per 120 mL formula or per breastfeeding</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pancrelipase: 2,000 to 4,000 units per 120 mL formula or per breastfeeding</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pertzye, Ultresa: 4,000 units per 120 mL formula or per breastfeeding</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Zenpep: 3,000 units per 120 mL formula or per breastfeeding</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> CF Guidelines recommend a dose of 2,000 to 5,000 units per feeding of formula, breast milk, or per breastfeeding (even if volume is &lt;120 mL) up to 2 years of age. Maximum daily dose: 10,000 lipase units/kg/day (Borowitz 2009; Borowitz 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;1 and &lt;4 years (Pertzye, Ultresa, Creon, Pancreaze, Zenpep): Oral: Initial: Lipase 1,000 units/kg/meal. Dosage range: Lipase 1,000 to 2,500 units/kg/meal. Maximum: Lipase &le;2,500 units/kg/<b>meal</b> <b>or</b> lipase &le;10,000 units/kg/<b>day</b> <b>or</b> lipase &lt;4,000 units/g of fat daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;4 years and Adolescents (Pertzye, Ultresa, Creon, Pancreaze, Zenpep): Oral: Initial: Lipase 500 units/kg/meal. Dosage range: Lipase 500 to 2,500 units/kg/meal. Maximum: Lipase &le;2,500 units/kg/<b>meal or</b> lipase &le;10,000 units/kg/<b>day or</b> lipase &lt;4,000 units/g of fat daily. In older patients, doses expressed as lipase units/kg/meal should be decreased as these patients tend to weigh more but ingest less fat per kg of body weight.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206072\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22123984\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22123985\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206051\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, delayed release, bicarbonate buffered enteric coated microspheres, oral [porcine derived]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pertzye: Lipase 4,000 USP units, protease 14,375 USP units, and amylase 15,125 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pertzye: Lipase 8,000 USP units, protease 28,750 USP units, and amylase 30,250 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pertzye: Lipase 16,000 USP units, protease 57,500 USP units, and amylase 60,500 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pertzye: Lipase 24,000 USP units, protease 86,250 USP units, and amylase 90,750 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, delayed release, enteric coated beads, oral [porcine derived]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pancrelipase (Lip-Prot-Amyl): Lipase 5000 USP units, protease 17,000 USP units, amylase 27,000 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zenpep: Lipase 3000 USP units, protease 10,000 USP units, and amylase 16,000 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zenpep: Lipase 5000 USP units, protease 17,000 USP units, and amylase 27,000 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zenpep: Lipase 10,000 USP units, protease 34,000 USP units, and amylase 55,000 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zenpep: Lipase 15,000 USP units, protease 51,000 USP units, and amylase 82,000 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zenpep: Lipase 20,000 USP units, protease 63,000 USP units, and amylase 84,000 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zenpep: Lipase 25,000 USP units, protease 85,000 USP units, and amylase 136,000 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zenpep: Lipase 40,000 USP units, protease 126,000 USP units, and amylase 168,000 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zenpep: Lipase 40,000 USP units, protease 136,000 USP units, and amylase 218,000 USP units [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, delayed release, enteric coated microspheres, oral [porcine derived]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Creon: Lipase 3000 USP units, protease 9500 USP units, and amylase 15,000 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Creon: Lipase 6000 USP units, protease 19,000 USP units, and amylase 30,000 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Creon: Lipase 12,000 USP units, protease 38,000 USP units, and amylase 60,000 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Creon: Lipase 24,000 USP units, protease 76,000 USP units, and amylase 120,000 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Creon: Lipase 36,000 USP units, protease 114,000 USP units, and amylase 180,000 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, delayed release, enteric coated microtablets, oral [porcine derived]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pancreaze: Lipase 2600 USP units, protease 6200 USP units, and amylase 10,850 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pancreaze: Lipase 4200 USP units, protease 14,200 USP units, and amylase 24,600 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pancreaze: Lipase 10,500 USP units, protease 35,500 USP units, and amylase 61,500 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pancreaze: Lipase 16,800 USP units, protease 56,800 USP units, and amylase 98,400 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pancreaze: Lipase 21,000 USP units, protease 54,700 USP units, and amylase 83,900 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, delayed release, enteric coated minitablets, oral [porcine derived]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ultresa: Lipase 13,800 USP units, protease 27,600 USP units, and amylase 27,600 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ultresa: Lipase 20,700 USP units, protease 41,400 USP units, and amylase 41,400 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ultresa: Lipase 23,000 USP units, protease 46,000 USP units, and amylase 46,000 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral [porcine derived]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Viokace: Lipase 10,440 USP units, protease 39,150 USP units, and amylase 39,150 USP units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Viokace: Lipase 20,880 USP units, protease 78,300 USP units, and amylase 78,300 USP units</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206037\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7990592\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Creon: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020725s016lbl.pdf#page=16&amp;token=SFMF4rwN93i9Sw1Khu0dV4RrWAim8HRCHbjchVEWMpOG8HBWythDwwmWDeIDWKv4PIC2ggx6Dm94VC2Ug8lMJUJiLMbqd4CSlDcREyq7AMjTdnb2DkBPg7ocNxFtzl9Z&amp;TOPIC_ID=9737\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020725s016lbl.pdf#page=16</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pancreaze: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM208531.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68pRE7wfNz9Ckjp/0Yy1p4ew==&amp;TOPIC_ID=9737\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM208531.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pertzye: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM306861.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WiOEnVHUaMn2P3VyQzI+ziA==&amp;TOPIC_ID=9737\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM306861.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ultresa: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM296221.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV687/uyJuWpSYmBLTS09t9wqw==&amp;TOPIC_ID=9737\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM296221.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Viokace: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM296222.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68kCs+TBSXuQ3rlaPK6Yszyg==&amp;TOPIC_ID=9737\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM296222.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Zenpep: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM180714.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQLVT3EIEyhU+YJU9SMqAncA==&amp;TOPIC_ID=9737\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM180714.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206054\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with meals or snacks and swallow whole with a generous amount of liquid. Do not crush or chew; retention in the mouth before swallowing may cause mucosal irritation. Usually half the prescribed dose for an individualized full meal should be given with each snack. The total daily dose should reflect approximately 3 meals plus 2 or 3 snacks per day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules, delayed release: If necessary, capsules may be opened and contents added to a small amount (approximately 10 mL) of soft acidic food (pH &le;4.5), such as applesauce; do not crush microspheres when mixing. The food should be swallowed immediately after mixing; do not chew. The food should be at room temperature (Creon, Ultresa). Follow with water or juice to ensure complete ingestion and that no medication remains in the mouth.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">When administering to infants &lt;1 year, do not mix with breast milk or infant formula. Open capsule and place the contents directly into the mouth or mix with approximately 10 mL of soft acidic food (pH &le;4.5), such as applesauce or other acidic commercially prepared baby food (pears or bananas); do not crush microspheres when mixing. The food should be at room temperature (Creon, Ultresa). Administer immediately after mixing (or within 15 minutes of mixing using Pancreaze). Follow with infant formula or breast milk to ensure complete ingestion and that no medication remains in the mouth.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Viokace: Tablets are not enteric coated and should be taken with a proton pump inhibitor.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Administration via gastrostomy (G) tube:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Creon: An in vitro study demonstrated that Creon delayed-release capsules sprinkled onto a small amount of baby food (pH &lt;4.5; applesauce or bananas manufactured by both Gerber and Beech-Nut) stirred gently and after 15 minutes was administered through the following G-tubes without significant loss of lipase activity: Kimberly-Clark MIC Bolus size 18 French, Kimberly-Clark MIC-KEY size 16 French, Bard Tri-Funnel size 18 French, and Bard Button size 18 French (Shlieout 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Pertzye: May administer up to two 4,000 unit capsules via G-tube with a diameter of 14 French or larger diameter tube. Thoroughly mix contents of one or two 4,000 unit capsules in &ge;10 mL applesauce to create a uniform suspension; do not crush microspheres. Administer via a 35 mL slip tip syringe; flush with ~10 mL of water. Administer immediately after mixing; do not save for later use. If dose requires &gt; two 4,000 unit capsules, repeat.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206053\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pancreatic insufficiency (exocrine):</b> Treatment of exocrine pancreatic insufficiency caused by cystic fibrosis or other conditions. Creon is also approved for patients with chronic pancreatitis or pancreatectomy. Viokace, in combination with a proton-pump inhibitor, is approved for use in adults with exocrine pancreatic insufficiency caused by chronic pancreatitis or pancreatectomy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Note:</b> Viokace must be administered with a proton pump inhibitor (PPI) since it is not enteric coated. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7828225\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pancrelipase may be confused with pancreatin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206044\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">The following adverse reactions were reported in a short-term safety studies; actual frequency varies with different products; adverse events, particularly gastrointestinal events, were often greater with placebo.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (3% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (3% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Lymphadenopathy (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Streptococcal infection (beta-hemolytic streptococcus: 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Neck pain (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otalgia (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasal congestion (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (4% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperglycemia (4% to 8%), weight loss (3% to 6%), exacerbation of diabetes mellitus (4%), hypoglycemia (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (10%), diarrhea (&le;10%), flatulence (3% to 9%), choledocholithiasis (7%), pruritus ani (7%), early satiety (6%), vomiting (6%), upper abdominal pain (&le;5%), abnormal stools (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Ascites (3%), hydrocholecystis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Viral infection (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal cyst (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (4% to 10%), epistaxis (7%), pharyngolaryngeal pain (7%), nasopharyngitis (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports (reported with various formulations of pancrelipase): Anaphylaxis, asthma, blurred vision, carcinoma (recurrence), constipation, duodenitis, fibrosing colonopathy, gastritis, hyperuricemia, increased serum transaminases (asymptomatic), intestinal obstruction (distal intestinal obstruction syndrome [DIOS]), muscle spasm, myalgia, nausea, neutropenia (transient), pruritus, severe hypersensitivity, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206057\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206041\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fibrosing colonopathy: Fibrosing colonopathy, advancing to colonic strictures, has been reported (rarely). Risk may be increased with high doses, prolonged use, and in pediatric patients with cystic fibrosis; however, the mechanism is unknown. Doses of lipase &gt;6,000 units/kg/meal have been associated with colonic stricture in children &lt;12 years. Patients taking doses of lipase &gt;6,000 units/kg/meal should be examined and the dose decreased. Doses of lipase &gt;2,500 units/kg/meal, lipase &gt;10,000 units/kg/day, or lipase &gt;4,000 units/g fat daily should be used with caution and only with documentation of effectiveness by 3-day fecal fat measures indicating a significantly improved coefficient of fat absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Severe, allergic reactions (eg anaphylaxis, asthma, hives, pruritus) have rarely been observed; use with caution in patients hypersensitive to pork proteins, taking into consideration the patient's overall clinical needs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mucosal irritation: Crushing or chewing the contents of the capsules or tablets, or mixing the capsule contents with foods outside of product labeling, may cause early release of the enzymes, causing irritation of the oral mucosa and/or loss of enzyme activity. When mixing the contents of capsules with food, the mixture should be swallowed immediately and followed with water or juice to ensure complete ingestion. Pancrelipase should not be mixed in foods with pH &gt;4.5.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pork: Products are derived from porcine pancreatic glands. Transmission of porcine viruses, and diseases caused by novel or unidentified viruses, is theoretically a risk; however, testing and/or inactivation or removal of certain viruses, reduces the risk. There have been no cases of transmission of an infectious illness reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gout, hyperuricemia: Use caution in patients with gout or hyperuricemia; porcine-derived products contain purines which may increase uric acid concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatic cancer: According to guidelines from the American Society of Clinical Oncology, patients with pancreatic cancer (potentially curable, locally advanced, or metastatic) who experience exocrine pancreatic insufficiency may require pancreatic enzyme replacement therapy to improve digestion and nutrient absorption (Balaban 2016; Khorana 2016; Sohal 2016). A retrospective study in patients with metastatic pancreatic cancer suggests that pancreatic enzyme replacement therapy is underutilized (Landers 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution in patients with renal impairment; porcine-derived products contain purines which may increase uric acid concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Brand interchangeability: Available brand products are <b>not</b> interchangeable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Viokace tablets may contain lactose; use with caution in patients with lactose intolerance.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299815\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222114\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9737&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206066\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Delayed release capsules: Enteric coated contents of delayed release capsules opened and sprinkled on alkaline foods may result in early release of pancrelipase followed by enzyme inactivation by gastric acid in the stomach after swallowing. Management: Avoid placing contents of opened capsules on alkaline food (using soft acidic foods with a pH of &le;4.5 is recommended for patients who cannot swallow capsules).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206047\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7990593\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Nutrition should be optimized in pregnancy; in cystic fibrosis patients with malabsorption, pancreatic enzyme replacement is not considered to cause a risk to the pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206060\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if pancrelipase is excreted in breast milk. The manufacturer recommends that caution be exercised when administering pancrelipase to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206061\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Take with meals or snacks and swallow whole with a generous amount of liquid. Capsule contents may be sprinkled on a soft acidic food with pH &lt;4.5. Vitamin supplementation should be per current guidelines for patients with cystic fibrosis. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206049\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Abdominal symptoms, nutritional intake, weight, growth (in children), stool character, fecal fat</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206040\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pancrelipase is a natural product harvested from the porcine pancreatic glands. It contains a combination of lipase, amylase, and protease. Products are formulated to dissolve in the more basic pH of the duodenum so that they may act locally to break down fats, protein, and starch.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206056\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: None; acts locally in GI tract </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323605\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, enteric pellets</b> (Creon Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000-9500 unit (70): $103.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6000 unit (100): $175.81</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12000 unit (100): $351.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">24000-76000 unit (100): $696.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">36000 unit (100): $1,057.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, enteric pellets</b> (Pancreaze Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2600 unit (100): $89.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4200 unit (100): $144.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10500 unit (100): $360.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">16800 unit (100): $578.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">21000 unit (100): $720.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, enteric pellets</b> (Pertzye Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4000 unit (100): $177.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8000 unit (100): $263.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">16000 unit (100): $527.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">24000-86250 unit (80): $633.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, enteric pellets</b> (Zenpep Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000-10000 unit (100): $194.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000 unit (100): $185.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000-24000 unit (100): $185.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000 unit (100): $367.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15000 unit (100): $530.27</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20000-63000 unit (100): $720.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25000 unit (100): $891.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25000-79000 unit (100): $891.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40000-126000 unit (100): $1,421.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Viokace Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10440 unit (100): $352.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20880 unit (100): $695.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038716\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>A Zyme (BD);</li>\n      <li>Creon (AR, AT, AU, BE, BR, CH, CN, CR, DK, DO, EC, FI, FR, GR, GT, HK, HN, IE, IL, IS, IT, JO, LU, MT, MX, MY, NI, NL, NO, NZ, PA, PH, SE, SV, TH, TR, VN, ZA);</li>\n      <li>Creon 10000 (AE);</li>\n      <li>Creon Forte (NL);</li>\n      <li>Dipankrin (HU);</li>\n      <li>Festal-N (IN);</li>\n      <li>Kreon (AT, CZ, DE, DK, ES, HR, HU, LT, LV, NO, PL, PT, RO, RU, SI, SK, UA);</li>\n      <li>Kreon 10000 (LB);</li>\n      <li>Lipacreon (JP);</li>\n      <li>Luizym (PT);</li>\n      <li>Mezym (LV, RO);</li>\n      <li>Mezym Forte (BG, HU, RO);</li>\n      <li>Neo-Pancreatinum (PL);</li>\n      <li>Neo-Panpur (HU);</li>\n      <li>Norzyme (KR, SG);</li>\n      <li>Orozim (VE);</li>\n      <li>Ozym (DE);</li>\n      <li>Pancrease (GR);</li>\n      <li>Pancrease HL (GB);</li>\n      <li>Pancrease MicroTabs (DK);</li>\n      <li>Pancrefar (PT);</li>\n      <li>Pancreolan Forte (CZ);</li>\n      <li>Pancrestal (BD);</li>\n      <li>Pancrex (IT);</li>\n      <li>Pancrin (AT);</li>\n      <li>Pancrit (BD);</li>\n      <li>Pangrol (CZ, HR, HU, PL, RO, RU);</li>\n      <li>Pankreatin (DE);</li>\n      <li>Pankreoflat (ES, KW, QA, SA);</li>\n      <li>Pankreon (VE);</li>\n      <li>Panzynorm (CZ);</li>\n      <li>Panzytrat (AU, HU);</li>\n      <li>Renzyme (BD);</li>\n      <li>Suzyme (BD);</li>\n      <li>Trepetan (MX);</li>\n      <li>Zymet (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Baker SS, &ldquo;Delayed Release Pancrelipase for the Treatment of Pancreatic Exocrine Insufficiency Associated With Cystic Fibrosis,&rdquo; <i>Ther Clin Risk Manag</i>, 2008, 4(5):1079-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancrelipase-drug-information/abstract-text/19209287/pubmed\" target=\"_blank\" id=\"19209287\">19209287</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline [published online ahead of print May 31, 2016]. <i>J Clin Oncol</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancrelipase-drug-information/abstract-text/27247216/pubmed\" target=\"_blank\" id=\"27247216\">27247216</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borowitz D, Baker RD, and Stallings V, &ldquo;Consensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis,&rdquo; <i>J Pediatr Gastroenterol Nutr</i>, 2002, 35(3):246-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancrelipase-drug-information/abstract-text/12352509/pubmed\" target=\"_blank\" id=\"12352509\">12352509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borowitz D, Robinson KA, Rosenfeld M, et al; Cystic Fibrosis Foundation. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. <i>J Pediatr</i>. 2009;155:S73-S93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancrelipase-drug-information/abstract-text/19914445/pubmed\" target=\"_blank\" id=\"19914445\">19914445</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borowitz DS, Grand RJ, and Durie PR, &ldquo;Use of Pancreatic Enzyme Supplements for Patients With Cystic Fibrosisin the Context of Fibrosing Colonopathy. Consensus Committee,&rdquo; <i>J Pediatr</i>, 1995, 127(5):681-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancrelipase-drug-information/abstract-text/7472816/pubmed\" target=\"_blank\" id=\"7472816\">7472816</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Creon (pancrelipase) [prescribing information]. North Chicago, IL: AbbVie; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Damerla V, Gotlieb V, Larson H, Saif MW. Pancreatic enzyme supplementation in pancreatic cancer. <i>J Support Oncol</i>. 2008;6(8):393-396.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancrelipase-drug-information/abstract-text/19149324/pubmed\" target=\"_blank\" id=\"19149324\">19149324</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edenborough FP, Borgo G, Knoop C, et al, &ldquo;Guidelines for the Management of Pregnancy in Women With Cystic Fibrosis,&rdquo; <i>J Cyst Fibros</i>, 2008, 7 Suppl 1:2-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancrelipase-drug-information/abstract-text/18024241/pubmed\" target=\"_blank\" id=\"18024241\">18024241</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FitzSimmons SC, Burkhart GA, Borowitz D, et al, &ldquo;High-Dose Pancreatic-Enzyme Supplements and Fibrosing Colonopathy in Children With Cystic Fibrosis,&rdquo; <i>N Engl J Med</i>, 1997, 336(18):1283-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancrelipase-drug-information/abstract-text/9113931/pubmed\" target=\"_blank\" id=\"9113931\">9113931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline [published online ahead of print May 31, 2016]. <i>J Clin Oncol</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancrelipase-drug-information/abstract-text/27247221/pubmed\" target=\"_blank\" id=\"27247221\">27247221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Landers A, Muircroft W, Brown H. Pancreatic enzyme replacement therapy (PERT) for malabsorption in patients with metastatic pancreatic cancer. <i>BMJ Support Palliat Care</i>. 2016;6(1):75-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancrelipase-drug-information/abstract-text/25164613/pubmed\" target=\"_blank\" id=\"25164613\">25164613</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pancreaze (pancrelipase) [prescribing information]. Titusville, NJ: Jassen Pharmaceuticals; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pancrelipase (pancrelipase) [prescribing information]. Big Flats, NY: X-Gen Pharmaceuticals; April 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pertzye (pancrelipase) [prescribing information]. Bethlehm, PA: Digestive Care, Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pettei MJ, Leonidas JC, Levinne JJ, et al, &ldquo;Pancolonic Disease in Cystic Fibrosis and High-Dose Pancreatic Enzyme Therapy,&rdquo; <i>J Pediatr</i>, 1994, 125(4):587-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancrelipase-drug-information/abstract-text/7931879/pubmed\" target=\"_blank\" id=\"7931879\">7931879</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shlieout G, Koerner A, Maffert M, et al, &ldquo;Administration of CREON Pancrelipase Pellets via Gastrostomy Tube is Feasible With No Loss of Gastric Resistance or Lipase Activity,&rdquo; <i>Clin Drug Investig</i>, 2011, 31(7):e1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancrelipase-drug-information/abstract-text/21627335/pubmed\" target=\"_blank\" id=\"21627335\">21627335</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sohal DP, Mangu PB, Khorana AA, et al. Metastatic pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline [published online ahead of print May 31, 2016]. <i>J Clin Oncol</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancrelipase-drug-information/abstract-text/27247222/pubmed\" target=\"_blank\" id=\"27247222\">27247222</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stallings VA, Stark LJ, Robinson KA, et al, &ldquo;Evidence-Based Practice Recommendations for Nutrition-Related Management of Children and Adults With Cystic Fibrosis and Pancreatic Insufficiency: Results of a Systematic Review,&rdquo; <i>J Am Diet Assoc</i>, 2008, 108(5):832-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancrelipase-drug-information/abstract-text/18442507/pubmed\" target=\"_blank\" id=\"18442507\">18442507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor CG, &ldquo;Colonic Strictures in Cystic Fibrosis,&rdquo; <i>Lancet</i>, 1994, 343(8898):615-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancrelipase-drug-information/abstract-text/7906805/pubmed\" target=\"_blank\" id=\"7906805\">7906805</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ultresa (pancrelipase) [prescribing information]. Birmingham, AL: Aptalis Pharma US Inc; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viokace (pancrelipase) [package insert]. Birmingham, AL: Aptalis Pharma US, Inc, March, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenpep (pancrelipase) [package insert]. Yardley, PA: Eurand Pharmaceuticals; September 2014.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9737 Version 130.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F206069\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F206070\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F206097\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F206071\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F206085\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F206072\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22123984\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22123985\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F206051\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F206037\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7990592\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F206054\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F206053\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7828225\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F206044\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F206057\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F206041\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299815\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222114\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F206066\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F206047\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7990593\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F206060\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F206061\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F206049\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F206040\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F206056\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323605\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038716\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9737|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pancrelipase-patient-drug-information\" class=\"drug drug_patient\">Pancrelipase: Patient drug information</a></li><li><a href=\"topic.htm?path=pancrelipase-pediatric-drug-information\" class=\"drug drug_pediatric\">Pancrelipase: Pediatric drug information</a></li></ul></div></div>","javascript":null}